Treatment Planning for Cardiac Radioablation: Multicenter Multiplatform Benchmarking for the RAdiosurgery for VENtricular TAchycardia (RAVENTA) Trial.


Journal

International journal of radiation oncology, biology, physics
ISSN: 1879-355X
Titre abrégé: Int J Radiat Oncol Biol Phys
Pays: United States
ID NLM: 7603616

Informations de publication

Date de publication:
15 06 2022
Historique:
received: 03 01 2022
revised: 15 05 2022
accepted: 05 06 2022
pubmed: 19 6 2022
medline: 9 9 2022
entrez: 18 6 2022
Statut: epublish

Résumé

Cardiac radioablation is a novel treatment option for patients with refractory ventricular tachycardia unsuitable for catheter ablation. The quality of treatment planning depends on dose specifications, platform capabilities, and experience of the treating staff. To harmonize the treatment planning, benchmarking of this process is necessary for multicenter clinical studies such as the RAdiosurgery for VENtricular TAchycardia trial. Planning computed tomography data and consensus structures from 3 patients were sent to 5 academic centers for independent plan development using a variety of platforms and techniques with the RAdiosurgery for VENtricular TAchycardia study protocol serving as guideline. Three-dimensional dose distributions and treatment plan details were collected and analyzed. In addition, an objective relative plan quality ranking system for ventricular tachycardia treatments was established. For each case, 3 coplanar volumetric modulated arc (VMAT) plans for C-arm linear accelerators (LINAC) and 3 noncoplanar treatment plans for robotic arm LINAC were generated. All plans were suitable for clinical applications with minor deviations from study guidelines in most centers. Eleven of 18 treatment plans showed maximal one minor deviation each for target and cardiac substructures. However, dose-volume histograms showed substantial differences: in one case, the planning target volume ≥30 Gy ranged from 0.0% to 79.9% and the ramus interventricularis anterior V Cardiac radioablation is feasible with robotic arm and C-arm LINAC systems with comparable plan quality. Although cross-center training and best practice guidelines have been provided, further recommendations, especially for cardiac substructures, and ranking of dose guidelines will be helpful to optimize cardiac radioablation outcomes.

Identifiants

pubmed: 35716847
pii: S0360-3016(22)00599-5
doi: 10.1016/j.ijrobp.2022.06.056
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

360-372

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Auteurs

Anne Kluge (A)

Klinik für Radioonkologie und Strahlentherapie, Charité-Universitätsmedizin Berlin, Berlin, Germany. Electronic address: anne.kluge@charite.de.

Stefanie Ehrbar (S)

Klinik für Radio-Onkologie, Universitäts Spital Zürich, University of Zurich, Zürich, Switzerland.

Melanie Grehn (M)

Department of Radiation Oncology, University Medical Center Schleswig-Holstein, Kiel, Germany.

Jens Fleckenstein (J)

Department of Radiation Oncology, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Wolfgang W Baus (WW)

Department of Radiation Oncology and CyberKnife Center, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.

Frank-Andre Siebert (FA)

Department of Radiation Oncology, University Medical Center Schleswig-Holstein, Kiel, Germany.

Achim Schweikard (A)

University of Lübeck, Institute for Robotic and Cognitive Systems, Lübeck, Germany.

Nicolaus Andratschke (N)

Klinik für Radio-Onkologie, Universitäts Spital Zürich, University of Zurich, Zürich, Switzerland.

Michael C Mayinger (MC)

Klinik für Radio-Onkologie, Universitäts Spital Zürich, University of Zurich, Zürich, Switzerland.

Judit Boda-Heggemann (J)

Department of Radiation Oncology, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Daniel Buergy (D)

Department of Radiation Oncology, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Eren Celik (E)

Department of Radiation Oncology and CyberKnife Center, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.

David Krug (D)

Department of Radiation Oncology, University Medical Center Schleswig-Holstein, Kiel, Germany.

Boldizsar Kovacs (B)

Universitäres Herzzentrum, Klinik für Kardiologie, Universitäts Spital Zürich, University of Zurich, Zürich, Switzerland.

Ardan M Saguner (AM)

Universitäres Herzzentrum, Klinik für Kardiologie, Universitäts Spital Zürich, University of Zurich, Zürich, Switzerland.

Boris Rudic (B)

I. Medizinische Klinik, Universitätsmedizin Mannheim and German Center for Cardiovascular Research (DZHK), Partner Site Heidelberg/Mannheim, Mannheim, Germany.

Paula Bergengruen (P)

Klinik für Radioonkologie und Strahlentherapie, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Leif-Hendrik Boldt (LH)

Med. Klinik m.S. Kardiologie, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Annina Stauber (A)

Klinik III für Kardiologie, Angiologie, Pneumologie und Internistische Intensivmedizin, Universitätsklinikum Köln, Köln, Germany.

Adrian Zaman (A)

Klinik für Innere Medizin III, Abteilung für Elektrophysiologie und Rhythmologie, Universitätsklinikum Schleswig-Holstein, Kiel, Germany.

Hendrik Bonnemeier (H)

Klinik für Innere Medizin III, Abteilung für Elektrophysiologie und Rhythmologie, Universitätsklinikum Schleswig-Holstein, Kiel, Germany.

Jürgen Dunst (J)

Department of Radiation Oncology, University Medical Center Schleswig-Holstein, Kiel, Germany.

Volker Budach (V)

Klinik für Radioonkologie und Strahlentherapie, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Oliver Blanck (O)

Department of Radiation Oncology, University Medical Center Schleswig-Holstein, Kiel, Germany.

Felix Mehrhof (F)

Klinik für Radioonkologie und Strahlentherapie, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH